newsfilter
← Latest News
Business Wire·

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Management Available for One-to-One Meetings Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist